中国医药导报
中國醫藥導報
중국의약도보
CHINA MEDICAL HERALD
2015年
3期
24-28
,共5页
目的：探讨北京积水潭医院院内制剂补肾壮骨丸抗骨质疏松的药效学作用及其机制。方法6个月龄雌性SD大鼠60只,随机分为正常对照组、模型对照组、补肾壮骨丸低(1.2 g/kg)、中(2.4 g/kg)、高(4.8 g/kg)剂量组以及阳性药雷洛昔芬组,每组10只。双侧卵巢摘除术建立大鼠骨质疏松模型,去势手术1周后,补肾壮骨丸低、中、高剂量组及阳性药组分别灌胃给予不同剂量补肾壮骨丸混悬液及雷洛昔芬混悬液治疗12周,正常及模型对照组灌服等体积的生理盐水。分别检测血清碱性磷酸酶(ALP)、抗酒石酸酸性磷酸酶(TRAP)、甲状旁腺激素(PTH)、促甲状腺激素(CT)以及垂体-性腺轴相关激素雌二醇(E2)、睾酮(T)、黄体生成素(LH)、卵泡刺激素(FSH)含量；测定骨密度、骨生物力学性能。结果去势后,模型对照组血清ALP、TRAP、PTH活性显著升高(P<0.05或P<0.01),含量分别为(16.347±2.957)U/100 mL、(27.691±7.042)U/L、(45.829±17.007)pg/mL,CT水平显著下降,含量为(20.469±7.343)pg/mL,全股骨和股骨头骨密度为(0.1859±0.0137)、(0.1871±0.0193)g/cm2,股骨最大载荷为(63.448±17.540)N,最大挠度为(0.5848±0.1595)mm,均较正常对照组显著降低(P<0.05或P<0.01)；性激素E2和T含量显著降低(P<0.01),分别为(5.935±1.621)pg/mL、(3.382±1.405)ng/mL,促性腺激素LH和FSH水平明显上调(P<0.05),含量分别为(12.549±2.376)、(15.841±1.896)mU/mL；与模型对照组比较,补肾壮骨丸中、高剂量组ALP含量为(13.619±2.881)、(12.720±3.044)U/100 mL,TRAP含量为(20.904±6.454)、(19.933±5.988)U/L,PTH含量为(26.753±13.013)、(25.630±15.618)pg/mL,三者活性均显著下调(P<0.05或P<0.01)；高剂量组CT含量显著升高,为(28.350±7.827)pg/mL,中、高剂量组全股骨密度及高剂量组股骨头密度显著升高,分别为(0.2081±0.0113)、(0.2135±0.0139)、(0.2304±0.0290)g/cm2,高剂量组股骨最大载荷及挠度分别为(81.314±16.413)N、(0.7358±0.1488)mm,较模型组显著升高(P<0.05)；高剂量组E2、T显著升高(P<0.05或P<0.01),含量为(8.799±2.204)pg/mL、(5.086±1.668)ng/mL；中、高LH含量分别为(10.740±1.652)、(10.575±0.886)mU/mL,FSH含量分别为(13.244±2.089)、(13.348±2.170)mU/mL,二者水平均显著下调(均P<0.05)。结论补肾壮骨丸可有效纠正骨代谢异常,增加骨密度,增强生物力学性能,其发挥抗骨质疏松作用的部分机制与其调节垂体-性腺轴相关激素水平有关。
目的：探討北京積水潭醫院院內製劑補腎壯骨汍抗骨質疏鬆的藥效學作用及其機製。方法6箇月齡雌性SD大鼠60隻,隨機分為正常對照組、模型對照組、補腎壯骨汍低(1.2 g/kg)、中(2.4 g/kg)、高(4.8 g/kg)劑量組以及暘性藥雷洛昔芬組,每組10隻。雙側卵巢摘除術建立大鼠骨質疏鬆模型,去勢手術1週後,補腎壯骨汍低、中、高劑量組及暘性藥組分彆灌胃給予不同劑量補腎壯骨汍混懸液及雷洛昔芬混懸液治療12週,正常及模型對照組灌服等體積的生理鹽水。分彆檢測血清堿性燐痠酶(ALP)、抗酒石痠痠性燐痠酶(TRAP)、甲狀徬腺激素(PTH)、促甲狀腺激素(CT)以及垂體-性腺軸相關激素雌二醇(E2)、睪酮(T)、黃體生成素(LH)、卵泡刺激素(FSH)含量；測定骨密度、骨生物力學性能。結果去勢後,模型對照組血清ALP、TRAP、PTH活性顯著升高(P<0.05或P<0.01),含量分彆為(16.347±2.957)U/100 mL、(27.691±7.042)U/L、(45.829±17.007)pg/mL,CT水平顯著下降,含量為(20.469±7.343)pg/mL,全股骨和股骨頭骨密度為(0.1859±0.0137)、(0.1871±0.0193)g/cm2,股骨最大載荷為(63.448±17.540)N,最大撓度為(0.5848±0.1595)mm,均較正常對照組顯著降低(P<0.05或P<0.01)；性激素E2和T含量顯著降低(P<0.01),分彆為(5.935±1.621)pg/mL、(3.382±1.405)ng/mL,促性腺激素LH和FSH水平明顯上調(P<0.05),含量分彆為(12.549±2.376)、(15.841±1.896)mU/mL；與模型對照組比較,補腎壯骨汍中、高劑量組ALP含量為(13.619±2.881)、(12.720±3.044)U/100 mL,TRAP含量為(20.904±6.454)、(19.933±5.988)U/L,PTH含量為(26.753±13.013)、(25.630±15.618)pg/mL,三者活性均顯著下調(P<0.05或P<0.01)；高劑量組CT含量顯著升高,為(28.350±7.827)pg/mL,中、高劑量組全股骨密度及高劑量組股骨頭密度顯著升高,分彆為(0.2081±0.0113)、(0.2135±0.0139)、(0.2304±0.0290)g/cm2,高劑量組股骨最大載荷及撓度分彆為(81.314±16.413)N、(0.7358±0.1488)mm,較模型組顯著升高(P<0.05)；高劑量組E2、T顯著升高(P<0.05或P<0.01),含量為(8.799±2.204)pg/mL、(5.086±1.668)ng/mL；中、高LH含量分彆為(10.740±1.652)、(10.575±0.886)mU/mL,FSH含量分彆為(13.244±2.089)、(13.348±2.170)mU/mL,二者水平均顯著下調(均P<0.05)。結論補腎壯骨汍可有效糾正骨代謝異常,增加骨密度,增彊生物力學性能,其髮揮抗骨質疏鬆作用的部分機製與其調節垂體-性腺軸相關激素水平有關。
목적：탐토북경적수담의원원내제제보신장골환항골질소송적약효학작용급기궤제。방법6개월령자성SD대서60지,수궤분위정상대조조、모형대조조、보신장골환저(1.2 g/kg)、중(2.4 g/kg)、고(4.8 g/kg)제량조이급양성약뢰락석분조,매조10지。쌍측란소적제술건립대서골질소송모형,거세수술1주후,보신장골환저、중、고제량조급양성약조분별관위급여불동제량보신장골환혼현액급뢰락석분혼현액치료12주,정상급모형대조조관복등체적적생리염수。분별검측혈청감성린산매(ALP)、항주석산산성린산매(TRAP)、갑상방선격소(PTH)、촉갑상선격소(CT)이급수체-성선축상관격소자이순(E2)、고동(T)、황체생성소(LH)、란포자격소(FSH)함량；측정골밀도、골생물역학성능。결과거세후,모형대조조혈청ALP、TRAP、PTH활성현저승고(P<0.05혹P<0.01),함량분별위(16.347±2.957)U/100 mL、(27.691±7.042)U/L、(45.829±17.007)pg/mL,CT수평현저하강,함량위(20.469±7.343)pg/mL,전고골화고골두골밀도위(0.1859±0.0137)、(0.1871±0.0193)g/cm2,고골최대재하위(63.448±17.540)N,최대뇨도위(0.5848±0.1595)mm,균교정상대조조현저강저(P<0.05혹P<0.01)；성격소E2화T함량현저강저(P<0.01),분별위(5.935±1.621)pg/mL、(3.382±1.405)ng/mL,촉성선격소LH화FSH수평명현상조(P<0.05),함량분별위(12.549±2.376)、(15.841±1.896)mU/mL；여모형대조조비교,보신장골환중、고제량조ALP함량위(13.619±2.881)、(12.720±3.044)U/100 mL,TRAP함량위(20.904±6.454)、(19.933±5.988)U/L,PTH함량위(26.753±13.013)、(25.630±15.618)pg/mL,삼자활성균현저하조(P<0.05혹P<0.01)；고제량조CT함량현저승고,위(28.350±7.827)pg/mL,중、고제량조전고골밀도급고제량조고골두밀도현저승고,분별위(0.2081±0.0113)、(0.2135±0.0139)、(0.2304±0.0290)g/cm2,고제량조고골최대재하급뇨도분별위(81.314±16.413)N、(0.7358±0.1488)mm,교모형조현저승고(P<0.05)；고제량조E2、T현저승고(P<0.05혹P<0.01),함량위(8.799±2.204)pg/mL、(5.086±1.668)ng/mL；중、고LH함량분별위(10.740±1.652)、(10.575±0.886)mU/mL,FSH함량분별위(13.244±2.089)、(13.348±2.170)mU/mL,이자수평균현저하조(균P<0.05)。결론보신장골환가유효규정골대사이상,증가골밀도,증강생물역학성능,기발휘항골질소송작용적부분궤제여기조절수체-성선축상관격소수평유관。
Objective To explore the pesticide effect and mechanism of Bushenzhuanggu Pills on osteoporosis rats in-duced by ovariectomy. Methods Sixty 6-month old female SD rats were randomly divided into six different groups ac-cording to body mass:normal control group, model group, Bushenzhuanggu Pill low (1.2 g/kg), medium (2.4 g/kg) and high dose (4.8 g/kg) groups, while Raloxifene as the positive control drug, 10 rats in each group. All rats received o-variectomy to establish osteoporosis model except those in the normal control group. Rats in treatment groups were treated with intragastric administration of Bushenzhuanggu Pill suspl with different doses or positive drug respectively for twelve weeks. Later the content of alkaline phosphatase (ALP), tartrate-resistant acid phosphatase (TRAP), parathy-roid hormone (PTH), osteocalcin (CT), bone mineral density (BMD), biomechanical efficiency, pathomorphology were observed. Also the levels of estradiol (E2), testosterone (T), luteinizing hormone (LH) and follicle stimulating hormone (FSH) were detected. Results The content of serum ALP, TRAP and PTH were significantly higher (P< 0.05 or P<0.01), the content was (16.347±2.957) U/100 mL, (27.691±7.042)U/L, (45.829±17.007) pg/mL respectively, while CT level was lower than normal control group by (20.469±7.343) pg/mL. Also reduction in BMD and biomechanical effi-ciency were observed (P<0.05 or P<0.01), the femur and femoral head bone density were (0.1859±0.0137) g/cm2 and (0.1871±0.0193) g/cm2, then the maximum load of femoral was (63.448±17.540) N, the maximum deflection was (0.5848±0.1595) mm. In addition, the content of serum E2 and T was significantly lower (P<0.01), contents of (5.935±1.621) pg/mL, (3.382±1.405) ng/mL, while the level of LH and FSH was significantly higher in ovariectomy rats (P<0.05), contents of (12.549±2.376), (15.841±1.896) mU/mL. Compared with model group, ALP content in the middle and high dose group of Bushenzhuanggu Pill were (13.619±2.881) and (12.720±3.044) U/100 mL, TRAP content was (20.904±6.454) and (19.933±5.988) U/L, the PTH content were (26.753±13.013) and (25.630±15.618) pg/mL, the three activities were significantly down regulated (P<0.05 or P<0.01). Content of CT in high dose group increased, as (28.350±7.827) pg/mL. The whole femur density in middle and high dose group and the density of the femoral head in high dose group significantly increased; bone density were (0.2081±0.0113), (0.2135±0.0139) and (0.2304±0.0290) g/cm2 respectively. The maximum load of femoral and radial in high dose group were (81.314±16.413) N and (0.7358±0.1488) mm, these in-dicators were compared to the model group increased significantly (P<0.05). Also treated group could significantly increase the content of sex hormone, while down-regulate the level of gonadotrophic hormone. The content of E2 and T in high dose group significantly increased (P<0.05 or P<0.01), content were (8.799±2.204) pg/mL and (5.086±1.668) ng/mL. The content of LH in middle and high dose group were (10.740±1.652) and (10.575±0.886) mU/mL respectively (P<0.05), while the content of FSH were (13.244±2.089) and (13.348±2.170) mU/mL respectively (P<0.05), the two levels were significantly lowered. Conclusion Bushenzhuanggu Pill can effectively correct abnormality of bone metabolism, increase bone density, enhance biomechanical properties of bone and reverse pathological changes in bone tissue. The mechanism of its anti-osteoporosis is related to the effect of regulating related hormones levels of thepituitary-gonadal axis.
